Breaking News Instant updates and real-time market news.

AGN

Allergan

$170.27

-0.655 (-0.38%)

, ABT

Abbott

$62.63

-0.28 (-0.45%)

08:08
06/14/18
06/14
08:08
06/14/18
08:08

Allergan announces Thomas Freyman to join Board of Directors

Allergan (AGN) announced that Thomas Freyman will join its Board of Directors effective immediately, as part of the company's ongoing board refreshment process. Freyman, a former Executive Vice President of Finance and Administration at Abbott Laboratories (ABT), brings nearly 40 years of healthcare industry and finance experience to Allergan's Board.

AGN

Allergan

$170.27

-0.655 (-0.38%)

ABT

Abbott

$62.63

-0.28 (-0.45%)

AGN Allergan
$170.27

-0.655 (-0.38%)

06/13/18
WELS
06/13/18
NO CHANGE
Target $240
WELS
Outperform
Wells Fargo encouraged by data for Allergan's glaucoma treatment
Wells Fargo analyst David Maris said he was encouraged by the positive topline results reported by Allergan from the first of two Phase 3 studies of its glaucoma treatment Bimatoprost SR, which he believes will eventually strengthen the company's commercial glaucoma franchise. He projects Bimatoprost SR to enter the market in 2020 and grow to sales of $280M in 2022. Maris keeps an Outperform rating on Allergan shares.
06/12/18
LEER
06/12/18
NO CHANGE
LEER
Too early to see Allergan's atogepant threatening injectables, says Leerink
Leerink analyst Geoffrey Porges notes that Allergan (AGN) announced positive topline data from a phase IIb/III trial of oral CGRP receptor antagonist atogepant in episodic migraine prevention. The analyst believes this data is certainly positive for Allergan and suggests they may eventually have an oral CGRP medicine approval for both acute and preventative treatment of migraines, However, Porges awaits further data disclosure and larger patient numbers to be convinced about comparing the efficacy of atogepant to the more advanced injectable CGRP medicines in development. With regard to Amgen (AMGN) and Alder (ALDR), who both have injectable CGRP antibodies for migraine prevention, potential competitive erosion from orals is still several years away and he continues to see the more severe chronic migraine population as being a more meaningful commercial opportunity for this class.
06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/11/18
PIPR
06/11/18
NO CHANGE
Target $48
PIPR
Overweight
Biohaven molecules remain best in class after Allergan data, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says that while today's data for Allergan's (AGN) atogepant "are not bad," Biohaven's (BHVN) molecules are still best in class. Atogepant appears to be effective in preventing migraines for episodic patients and while the incidence of elevated liver enzymes was balanced between the arms, it is a risk that needs to be studied in larger and longer Phase III trials, Van Buren tells investors in a research note. Further, the analyst notes Allergan's data do not cure the observed imbalance in liver toxicity that was seen recently with ubrogepant, the direct competitor to Biohaven's rimegepant for acute migraine, in Phase III trials earlier this year. Van Buren keeps an Overweight rating on Biohaven with a $48 price target.
ABT Abbott
$62.63

-0.28 (-0.45%)

06/11/18
PIPR
06/11/18
NO CHANGE
Target $32.5
PIPR
Overweight
Piper doesn't see regulatory issues for possible Stryker, Boston Scientific deal
Piper Jaffray analyst Matt O'Brien believes regulatory constraints from Stryker's (SYK) potential acquisition of Boston Scientific (BSX) "should not be much of an issue" given the little overlap between the businesses. The deal structure would be the biggest issue facing Stryker as the company would likely have to lever up heavily to acquire Boston Scientific, O'Brien tells investors in a research note. The analyst believes a transaction could occur in the $52B-$54B range, assuming a typical medtech takeout premium of 20%-30%. Consequently, any transaction would either require a significant level of debt or dilution to Stryker shareholders, the analyst contends. He sees the potential deal as likely being dilutive until 2021. O'Brien has an Overweight rating on Boston Scientific with a $32.50 price target. The stock closed the trading day up 7% to $34.32 after the Wall Street Journal reported that Stryker approached the company regarding a takeover.
06/08/18
PIPR
06/08/18
NO CHANGE
Target $93
PIPR
Overweight
Some Abbott patients switching to DexCom, says Piper Jaffray
Piper Jaffray analyst JP McKim says his analysis of weekly script data suggests the drop-out rate for Abbott's (ABT) Libre is around 40%, or "much higher" than DexCom (DXCM). Further, some of those patients are indeed switching to DexCom's G6, which just launched last week, McKim tells investors in a research note. The analyst views G6 as an important growth driver for DexCom and suspects it will drive accelerating adoption in Type 1 diabetes for continuous glucose monitoring. The McKim has an Overweight rating on the shares with a $93 price target. JPMorgan this morning upgraded DexCom to Overweight.
06/08/18
JPMS
06/08/18
UPGRADE
Target $115
JPMS
Overweight
JPMorgan upgrades 'clear market leader' DexCom with $115 price target
JPMorgan analyst Robbie Marcus upgraded DexCom (DXCM) to Overweight from Neutral and raised his price target for the shares to $115 from $80. Glucose measurement is becoming an essential tool for patients and DexCom, with the launch of the G6, is the "clear market leader" from a technological standpoint, Marcus tells investors in a research note. Within two years the company is slated to have a low-cost, fully disposable option to counter Abbott's (ABT) Libre and address the Type 2 patient population, the analyst adds. He sees "significant upside" to both near-term estimates and Dexcom's product pipeline.
05/03/18
LSCM
05/03/18
NO CHANGE
Target $76
LSCM
Buy
Surmodics price target raised to $76 from $38 at Lake Street
Lake Street analyst Brooks O'Neil raised his price target for Surmodics (SRDX) to $76 after reconsidering the way he values the shares. The existing business is worth what the stock is trading for today, and SurVeil, the two other "high potential" products considered in the Abbott (ABT) agreement and the roughly 15 510 (K) products Surmodics is developing are worth about the same, O'Neil tells investors in a research note following the company's Q2 results. He keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

PDD

Pinduoduo

$20.26

-0.34 (-1.65%)

12:25
12/10/18
12/10
12:25
12/10/18
12:25
Options
Pinduoduo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
12/10/18
12/10
12:25
12/10/18
12:25
General news
Euro$ interest rate futures perked up »

Euro$ interest rate…

BCO

Brink's

$61.25

-0.85 (-1.37%)

12:22
12/10/18
12/10
12:22
12/10/18
12:22
Conference/Events
Brink's management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

QCOM

Qualcomm

$57.75

1.75 (3.13%)

, AAPL

Apple

$164.67

-3.7 (-2.20%)

12:20
12/10/18
12/10
12:20
12/10/18
12:20
Recommendations
Qualcomm, Apple analyst commentary  »

Injunction may be first…

QCOM

Qualcomm

$57.75

1.75 (3.13%)

AAPL

Apple

$164.67

-3.7 (-2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTRI

Nutrisystem

$44.15

9.96 (29.13%)

12:17
12/10/18
12/10
12:17
12/10/18
12:17
Downgrade
Nutrisystem rating change  »

Nutrisystem downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
12/10/18
12/10
12:17
12/10/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLD

TopBuild

$46.22

-0.96 (-2.03%)

12:16
12/10/18
12/10
12:16
12/10/18
12:16
Conference/Events
TopBuild management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

  • 13

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
12/10/18
12/10
12:16
12/10/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$49.62

-2.44 (-4.69%)

12:15
12/10/18
12/10
12:15
12/10/18
12:15
Options
Anadarko put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

CCK

Crown Holdings

$47.82

-0.22 (-0.46%)

12:14
12/10/18
12/10
12:14
12/10/18
12:14
Conference/Events
Crown Holdings to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRDXF

Nordex

$0.00

(0.00%)

12:13
12/10/18
12/10
12:13
12/10/18
12:13
Upgrade
Nordex rating change  »

Nordex upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:10
12/10/18
12/10
12:10
12/10/18
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY…

KO

Coca-Cola

$48.84

-0.24 (-0.49%)

12:08
12/10/18
12/10
12:08
12/10/18
12:08
Periodicals
Coca-Cola hires broker to sell iconic Fifth Avenue building, Bloomberg says »

Coca-Cola has enlisted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 18

    Dec

  • 03

    Mar

DLAKY

Lufthansa

$0.00

(0.00%)

, EADSY

Airbus

$0.00

(0.00%)

12:07
12/10/18
12/10
12:07
12/10/18
12:07
Periodicals
Avianca CEO wants to cut Airbus order by as much as half, Reuters says »

Avianca Holdings (AVH)…

DLAKY

Lufthansa

$0.00

(0.00%)

EADSY

Airbus

$0.00

(0.00%)

AVH

Avianca

$4.91

-0.39 (-7.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$165.25

-3.12 (-1.85%)

, QCOM

Qualcomm

$58.05

2.05 (3.66%)

12:06
12/10/18
12/10
12:06
12/10/18
12:06
OnTheFly
Fly Intel: Wall Street's top stories at midday »

The averages were…

AAPL

Apple

$165.25

-3.12 (-1.85%)

QCOM

Qualcomm

$58.05

2.05 (3.66%)

FB

Facebook

$140.74

3.32 (2.42%)

GPRO

GoPro

$4.94

-0.04 (-0.80%)

TVPT

Travelport

$15.68

0.275 (1.79%)

NTRI

Nutrisystem

$44.14

9.95 (29.10%)

TVTY

Tivity Health

$28.53

-12.07 (-29.73%)

XPER

Xperi

$18.34

5.54 (43.28%)

SSNLF

Samsung

$0.00

(0.00%)

MDRX

Allscripts

$10.15

0.66 (6.95%)

MGNX

MacroGenics

$12.00

-4.44 (-27.01%)

CRZO

Carrizo Oil & Gas

$14.69

-1.2 (-7.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

  • 11

    Dec

  • 12

    Dec

  • 12

    Dec

  • 06

    Jan

KZR

Kezar Life Sciences

$27.79

0.41 (1.50%)

12:05
12/10/18
12/10
12:05
12/10/18
12:05
Conference/Events
Kezar Life Sciences management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 12

    Dec

T

AT&T

$29.50

-0.64 (-2.12%)

12:05
12/10/18
12/10
12:05
12/10/18
12:05
Options
AT&T call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 20

    Mar

BC

Brunswick

$49.53

-0.05 (-0.10%)

12:02
12/10/18
12/10
12:02
12/10/18
12:02
Conference/Events
Brunswick management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

AJG

Arthur J. Gallagher

$73.87

-0.74 (-0.99%)

12:01
12/10/18
12/10
12:01
12/10/18
12:01
Hot Stocks
Arthur J. Gallagher acquires Captive Insurance Company Design and Operations »

Arthur J. Gallagher &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 11

    Dec

JP

Jupai Holdings

$5.06

-0.94 (-15.67%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Jupai Holdings falls -15.8% »

Jupai Holdings is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSC

Global Geoscience

$23.90

(0.00%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Global Geoscience falls -16.2% »

Global Geoscience is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPX

Marine Products

$18.19

-3.4 (-15.75%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Marine Products falls -18.3% »

Marine Products is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPER

Xperi

$18.39

5.59 (43.67%)

, SSNLF

Samsung

$0.00

(0.00%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Recommendations
Xperi, Samsung analyst commentary  »

Xperi settlement removes…

XPER

Xperi

$18.39

5.59 (43.67%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 06

    Jan

FAZ

Direxion Financial Bear 3x

$12.50

0.67 (5.66%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Direxion Financial Bear 3x rises 5.8% »

Direxion Financial Bear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCUS

Arcus Biosciences

$13.15

0.9 (7.35%)

12:00
12/10/18
12/10
12:00
12/10/18
12:00
Hot Stocks
Arcus Biosciences rises 8.1% »

Arcus Biosciences is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.